IGI Logo

Cadila Healthcare is currently trading at Rs. 468.00, up by 5.35 points or 1.16% from its previous closing of Rs. 462.65 on the BSE.

The scrip opened at Rs. 462.50 and has touched a high and low of Rs. 469.05 and Rs. 461.75 respectively. So far 39534 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 673.70 on 12-May-2021 and a 52 week low of Rs. 408.40 on 19-Mar-2021.

Last one week high and low of the scrip stood at Rs. 466.65 and Rs. 447.10 respectively. The current market cap of the company is Rs. 47813.90 crore.

The promoters holding in the company stood at 74.88%, while Institutions and Non-Institutions held 15.43% and 9.69% respectively.

Zydus Cadila has received permission from the U.S. Food and Drug Administration (USFDA) to initiate the Phase 2(b)/3 Prospective, Multi-centre, Randomized, Double-blind, Placebo-controlled adaptive clinical trial to evaluate Efficacy and Safety of Saroglitazar Magnesium in Subjects With Primary Biliary Cholangitis (PBC).

The EPICS-III trial will randomise 192 subjects in a 1:1:1 ratio to Saroglitazar 1 mg, Saroglitazar 2 mg or Placebo and will study the Saroglitazar Magnesium (1 or 2 mg) relative to Placebo based on the composite endpoints of Alkaline Phosphatase (ALP),total bilirubin, liver stiffness measurement (LSM) by FibroScan, liver enzyme parameters (ALT, AST, GGT, total bilirubin, and albumin), lipid parameters (TG, LDL-C, HDL-C, VLDL-C, total cholesterol, and non-HDL-C), health related quality of life using PBC 40 questionnaire (a patient-derived, disease specific quality of life measure developed and validated for use in PBC) and other outcome measures over a period of 52 weeks.

Cadila Healthcare is an India-based pharmaceutical company. The company's subsidiaries include Zydus Wellness, Liva Pharmaceuticals, Biochem Pharmaceutical Industries, Zydus Technologies, German Remedies, Dialforhealth India, Dialforhealth Unity and Dialforhealth Greencross, among others.